Harvard researcher’s PhD revoked, former group earns three more retractions

Journal of Biological ChemistryA research fellow at Harvard has lost his PhD from a university in Singapore after being found guilty of falsifying data, and his former group leader’s contract has been terminated by his institution.

But that’s not the whole story. This tangled mess involves not only the Harvard researcher, Sudarsanareddy Lokireddy, and his former boss, Ravi Kambadur at the Nanyang Technological University (NTU) in Singapore, but an as-yet unnamed colleague of theirs who, we’re told, has admitted making up data in three papers, on which Lokireddy and Kambadur are co-authors. Bear with us as we walk you through this tale.

Two of those papers have been retracted by The Journal of Biological Chemistry (JBC); one in Molecular Endocrinology has yet to be pulled. Kambadur, who held joint appointments at the NTU and the Agency for Science, Research and Technology (A*STAR) in Singapore, has now had his contract terminated at both institutions.  Continue reading Harvard researcher’s PhD revoked, former group earns three more retractions

Researcher who sued to stop retractions earns his 7th

Mario Saad
Mario Saad

A diabetes researcher who sued to stop a publisher from retracting his papers has just received his seventh retraction.

The latest retraction for Mario Saad, who is based at the University of Campinas (Unicamp) in São Paulo, Brazil, is for a PLOS ONE paper (which was altered last year by a mega-correction). Although an institutional investigation found no evidence of research misconduct, the notice states:

the preparation of the figures falls below the standard of publication and therefore the authors and the editors have agreed that the correct action is to retract the article. 

Saad previously sued the American Diabetes Association (ADA) to remove expressions of concern from four of his papers published in the organisation’s flagship journal, Diabetes. However, all four of the papers were later retracted after the suit was dismissed in 2015.

Here’s the new retraction notice, issued July 8: Continue reading Researcher who sued to stop retractions earns his 7th

“We should err on the side of protecting people’s reputation:” Management journal changes policy to avoid fraud

Patrick Wright, via the University of South Carolina
Patrick Wright, via the University of South Carolina

How can academic journals ensure the integrity of the data they publish? For one journal, the key is looking deeply at statistics, which revealed crucial problems in the research of recent high-profile fraudsters such as Anil Potti. Editor-in-chief of the Journal of Management, Patrick Wright from the University of South Carolina, recently authored an editorial about how he’s taken those lessons to heart — and why he believes retractions don’t always hurt a journal’s reputation. 

RW: Can you take us through the changes in the editorial policy of your journal? Continue reading “We should err on the side of protecting people’s reputation:” Management journal changes policy to avoid fraud

Broken windows, threats, and detention: Is whistleblowing worth it?

Wyn Ellis
Wyn Ellis

Several years ago, a UK academic living in Thailand for decades decided to expose the fact that a Thai official had plagiarized his PhD thesis. And he’s paid the price. Last year, Wyn Ellis was held in a Thai airport for five days, as officials claimed he was a “danger to Thai society.” As some new developments have emerged in the case, Ellis ponders the after-effects of his actions.

This month marks the 4th anniversary of the very public revocation by Chulalongkorn University of the PhD degree of Supachai Lorlowhakarn, the former director of Thailand’s National Innovation Agency (NIA), for ethical violations, and plagiarism of his thesis.

For me, as the original whistleblower who first alerted authorities to the problems with Lorlowhakarn’s PhD thesis, the knowledge that justice was eventually served is far from cause for celebration. Indeed, the Byzantine twists and turns, the lawsuits, surveillance, physical attacks, and even death threats over the past nine years have — without a doubt — taken their toll on my family and I, and should serve as a salutary lesson to anyone harboring naive notions of civic duty. This was certainly my own motivation back then, as an advocate and passionate supporter of Thai science and innovation.

Here are some of the threats I encountered: Continue reading Broken windows, threats, and detention: Is whistleblowing worth it?

Second retraction for researcher who faked 70+ experiments

Journal of Biological ChemistryTwo researchers found to have faked data by the U.S. Office of Research Integrity (ORI) have lost a paper that they co-authored.

According to the ORI report issued on May 25, Ricky Malhotra, one of the researchers in question, admitted to fabricating 74 experiments, and falsifying well over 100 Western blots while at the Universities of Michigan (UM) and Chicago (UC). One week later, the ORI issued additional findings about Karen D’Souza, a colleague of Malhotra’s at the UC, concluding that she had also falsified some data.

Both researchers agreed to the retraction of a 2010 paper published in The Journal of Biological Chemistry (JBC), the reports note.

Here’s the retraction notice, issued on July 1: Continue reading Second retraction for researcher who faked 70+ experiments

Is the bulk of fMRI data questionable?

Anders Eklund
Anders Eklund, via Linköping University

Last week, a study brought into question years of research conducted using the neuroimaging technique functional magnetic resonance imaging (fMRI). The new paper, published in PNAS, particularly raised eyebrows for suggesting that the rates of false positives in studies using fMRI could be up to 70%, which may affect many of the approximately 40,000 studies in academic literature that have so far used the technique. We spoke to the Anders Eklund, from Linköping University in Sweden, who was the first author of the study. Continue reading Is the bulk of fMRI data questionable?

A prominent psychiatry researcher is dismissed. What’s happening to his papers?

neumeister
Alexander Neumeister. Source: Yale School of Medicine

After a prominent researcher was dismissed due to multiple instances of misconduct in his studies, how are journals responding?

When an investigation by the U.S. Food and Drug Administration (FDA) found multiple issues with the work of psychiatry researcher Alexander Neumeister, New York University (NYU) Langone Medical Center shut down eight of his studies. (Disclosure: The author of this post is an NYU journalism student, but has no relationship with the medical school.) The agency concluded the studies, which involved using experimental drugs to relieve symptoms of post-traumatic stress disorder (PTSD), were tainted by lax oversight, falsified records, and inaccurate case histories, according to the New York Times. (Neuroskeptic also recently analyzed the case.)

We reached out to the journals that have published Neumeister’s papers, to ask if these recent events have caused them to take a second look at his work. Several have responded, with some noting they plan to investigate, or will do so if asked by the institution. But many believe there is little cause for concern. Continue reading A prominent psychiatry researcher is dismissed. What’s happening to his papers?

Should a paper be retracted if an author omits a conflict of interest?

s-cover-yvs1606A JAMA journal has quickly issued a correction for a 2016 paper after the author failed to mention several relevant conflicts of interest. Normally, we’d see this as a run-of-the-mill correction notice, but since we reported last week that a journal retracted a paper for omitting pharma funding, we got to wondering: Is failure to disclose a conflict of interest a retractable offense?

Guidelines from the Committee on Publication Ethics (COPE) do say that retractions are used for “failure to disclose a major competing interest likely to influence interpretations or recommendations.” But most of the time when we see corrections to the literature for such omissions, they’re corrections, not retractions.

On Friday, JAMA Ophthalmology issued a correction notice for an invited commentary published in April, which addressed two papers in the journal about melanoma of the eye (uveal melanoma). However, the original commentary failed to note that author Arun D. Singh at the Cleveland Clinic had some relevant conflicts to mention, as the notice explains: Continue reading Should a paper be retracted if an author omits a conflict of interest?

Vast majority of Americans want to criminalize data fraud, says new study

court caseAs Retraction Watch readers know, criminal sanctions for research fraud are extremely rare. There have been just a handful of cases — Dong-Pyou Han, Eric Poehlman, and Scott Reuben, to name several — that have led to prison sentences.

According to a new study, however, the rarity of such cases is out of sync with with the wishes of the U.S. population:
Continue reading Vast majority of Americans want to criminalize data fraud, says new study

Weekend reads: Unscientific peer review; impact factor revolt; men love to cite themselves

booksThe week at Retraction Watch featured a puzzle, and the retraction of a controversial study on fracking. Here’s what was happening elsewhere: Continue reading Weekend reads: Unscientific peer review; impact factor revolt; men love to cite themselves